Recent advances in genome-wide studies have revealed numerous epigenetic regulations brought about by genes involved in cellular metabolism. Isocitrate dehydrogenase (IDH), an essential enzyme, that converts isocitrate into -ketoglutarate (KG) predominantly in the tricarboxylic acid (TCA) cycle, has gained particular importance due to its cardinal role in the metabolic pathway in cells. IDH1, IDH2, and IDH3 are the three isomeric IDH enzymes that have been shown to regulate cellular metabolism. Of particular importance, IDH2 genes are associated with several cancers, including gliomas, oligodendroglioma, and astrocytomas. These mutations lead to the production of oncometabolite D-2-hydroxyglutarate (D-2-HG), which accumulates in cells promoting tumor growth. The enhanced levels of D-2-HG competitively inhibit α-KG dependent enzymes, inhibiting cell TCA cycle, upregulating the cell growth and survival relevant HIF-1α pathway, promoting DNA hypermethylation related epigenetic activity, all of which synergistically contribute to carcinogenesis. The present review discusses epigenetic mechanisms inIDH2 regulation in cells and further its clinical implications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/bs.apcsb.2023.12.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Survival and immune microenvironment prediction of glioma based on MRI imaging genomics method: a retrospective observational study.
Neurosurg Rev
January 2025
Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
Glioma is characterized by high heterogeneity and poor prognosis. Attempts have been made to understand its diversity in both genetic expressions and radiomic characteristics, while few integrated the two omics in predicting survival of glioma. This study was intended to investigate the connection between glioma imaging and genome, and examine its predictive value in glioma mortality risk and tumor immune microenvironment (TIME).
View Article and Find Full Text PDFDesign, synthesis, biological evaluation and molecular docking of novel isatin-oxime ether derivatives as potential IDH1 inhibitors.
Mol Divers
January 2025
College of Chemistry and Materials Engineering, Zhejiang A&F University, Hangzhou, 311300, China.
A series of novel isatin-oxime ether derivatives were designed, synthesized and characterized by H NMR and C NMR and HRMS. These compounds were evaluated for their in vitro cytotoxicity against three human cancer cell lines (A549, HepG2 and Hela) by MTT assay. According to the experimental results, compounds 6a (IC = 0.
View Article and Find Full Text PDFS100A proteins show a spatial distribution of inflammation associated with the glioblastoma microenvironment architecture.
Theranostics
January 2025
Neurooncology Unit, Instituto de Investigación Biomédicas I+12, Hospital Universitario 12 de Octubre, Madrid 28041, Spain.
Article Synopsis
- GBM IDH wild type (GBM IDH wt) is linked to bad outcomes and intense inflammatory processes that help tumors grow and attract immune cells, making them more aggressive.
- Researchers utilized RNA-seq and bioinformatics tools to explore how inflammatory molecules, specifically S100A proteins, play a role in glioma, finding a notable increase in S100A expression in GBM IDH wt compared to IDH mutants.
- The study identified specific functions of S100A9, A11, and A13 in different regions of the glioma microenvironment, suggesting potential therapeutic strategies, such as using the RAGE inhibitor Azeliragon, currently in clinical trials, to counteract these inflammatory effects.
Effects of Radiotherapy Alone Versus Concomitant Radiotherapy With Temozolomide Chemotherapy on the Outcome of IDH-wildtype Glioblastoma Patients.
Clin Oncol (R Coll Radiol)
December 2024
Department of Neurosciences, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Background: Isocitrate dehydrogenase [IDH]-wildtype glioblastoma is an aggressive brain cancer associated with high recurrence and poor overall survival.
Aim: Our study aims to explore the prognostic effects of radiotherapy [RT] alone versus concomitant RT with temozolomide [TMZ].
Methods: A multicentre retrospective study included a cohort of 244 patients diagnosed with IDH-wildtype glioblastoma, and it was analysed from 2013 to 2020.
Evaluation of early metabolic changes following vorasidenib using FET PET in patients with -mutant gliomas.
Neurooncol Adv
November 2024
Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
The phase-3 INDIGO trial demonstrated that the isocitrate dehydrogenase () inhibitor vorasidenib significantly prolonged progression-free survival and delayed intervention in patients with CNS WHO grade 2 gliomas. However, conventional MRI showed limited response, with only 11% of patients having objective responses. Studies suggest that serial PET imaging with radiolabeled amino acids, such as -(2-[ F]-fluoroethyl)-L-tyrosine (FET) PET, may provide earlier and more informative assessments of treatment response than MRI.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!